참고문헌
- Babic T, Francis P, Palmer A, Snape M, Wilcock G. 1999. The cholinergic hypothesis of Alzheimer's disease: A review of progress. J Neurol Neurosurg Psychiatry 66:137-147 https://doi.org/10.1136/jnnp.66.2.137
- Benzi G, Moretti A, 1998. Is there a rationale for the use of acetylcholinesterase inhibitors in the therapy of Alzheimer's disease? Eur J Pharmacol 346:1-13 https://doi.org/10.1016/S0014-2999(98)00093-4
- Biederman J, Mick E, Faraone S, Hammerness P, Surman C, Harpold T, Dougherty M, Aleardi M, Spencer T. 2006. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol 26:163-166 https://doi.org/10.1097/01.jcp.0000204139.20417.8a
- Cubo E, Fernandez Jaen A, Moreno C, Anaya B, Gonzalez M, Kompoliti K. 2008. Donepezil use in children and adolescents with tics and attention-deficit/hyperactivity disorder: an 18-week, single-center, dose-escalating, prospective, openlabel study. Clin Ther 30:182-189 https://doi.org/10.1016/j.clinthera.2008.01.010
- Hirai S. 2000. Alzheimer disease: current therapy and future therapeutic strategies. Alzheimer Dis Assoc Disord 14 Suppl 1:S11-17
- Klinkenberg I, Blokland A. 2010. The validity of scopolamine as a pharmacological model for cognitive impairment: A review of animal behavioral studies. Neurosci Biobehav Rev 34:1307-1350 https://doi.org/10.1016/j.neubiorev.2010.04.001
- Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. 1999. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. Eur J Pharmacol 380:101-107 https://doi.org/10.1016/S0014-2999(99)00545-2
- Lee DS, Choi J, Kim SH, Kim S. 2014. Ameliorating effects of HX106N, a water-soluble botanical formulation, on Abetainduced memory impairment and oxidative stress in mice. Biol Pharm Bull 37:954-960 https://doi.org/10.1248/bpb.b13-00906
- Maurice T, Lockhart BP, Privat A. 1996. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res 706:181-193 https://doi.org/10.1016/0006-8993(95)01032-7
- Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. 1998. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 50:136-145 https://doi.org/10.1212/WNL.50.1.136
- Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. 1999. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 318: 633-638
- Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C. 2000. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54:2269-2276 https://doi.org/10.1212/WNL.54.12.2269
- Terry AV Jr, Buccafusco JJ. 2003. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306:821-827 https://doi.org/10.1124/jpet.102.041616
- Tran MH, Yamada K, Nabeshima T. 2002. Amyloid beta-peptide induces cholinergic dysfunction and cognitive deficits: A minireview. Peptides 23:1271-1283 https://doi.org/10.1016/S0196-9781(02)00062-1
피인용 문헌
- Effective suppression of nitric oxide production by HX106N through transcriptional control of heme oxygenase-1 vol.240, pp.9, 2015, https://doi.org/10.1177/1535370214567612